US Pharma Giant's Weight-Loss Pill Approved for Sale in Israel

The weight-loss medication, known by the brand name "Pill-a-Day" (or "Poundayou" in Hebrew transliteration) and medically as orforglipron, will be available in Israeli pharmacies starting September 15. Developed by American pharmaceutical giant Eli Lilly, Israel is the fourth country globally to approve the drug's marketing, following the United States, the United Kingdom, and the United Arab Emirates. The drug has been submitted for approval to the Israeli Ministry of Health and is being considered for inclusion in the national health basket.

Poundayou is designed to aid in weight reduction and maintenance for adults with obesity or overweight individuals who have at least one weight-related comorbidity, when used in conjunction with a reduced-calorie diet and increased physical activity. While effective, its weight-loss impact is reported to be about half that of injectable weight-loss medications.

Dr. Raz Haguel, Director of the Medical Center for Obesity Treatment, highlighted the convenience of a daily pill compared to injections, noting that Poundayou can be taken without fasting, specific timing relative to meals, or special restrictions on drinking. This simplicity, he explained, makes it a more accessible treatment option for patients to integrate into their daily routines. He emphasized that the growing variety of treatment options allows for more personalized care, catering to individual patient needs and preferences.

The medication is administered as a small pill taken once daily, allowing for absorption in the digestive system regardless of meal times or consumption of food or drink. It is available in six different dosages. A significant logistical advantage is that Poundayou does not require refrigeration, simplifying supply chains and patient convenience. The prices for the medication range from approximately 691.59 to 1,146.46 Israeli shekels, depending on the dosage.